Sclerostin and dickkopf-1 as therapeutic targets in bone diseases

Endocrine Reviews

Volumn 33, Issue 5, 2012, Pages 747-783

  Ke, Hua Zhu ^a   Richards, William G ^a   Li, Xiaodong ^a   Ominsky, Michael S ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; DICKKOPF 1 PROTEIN; GLUCOCORTICOID; PIOGLITAZONE; PROTEIN ANTIBODY; SCLEROSTIN; SCLEROSTIN ANTIBODY; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WNT PROTEIN;

AGE; AMINO ACID SEQUENCE; ARTICULAR CARTILAGE; BONE DENSITY; BONE DEVELOPMENT; BONE DISEASE; BONE METABOLISM; BONE MINERALIZATION; CHRONIC INFLAMMATION; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DRUG DOSE COMPARISON; DRUG TARGETING; ESTROGEN DEFICIENCY; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GROWTH PLATE; HUMAN; IMMOBILIZATION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSCLEROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SUBCHONDRAL BONE PLATE; WNT SIGNALING PATHWAY;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE DENSITY; BONE DISEASES, METABOLIC; BONE MORPHOGENETIC PROTEINS; BONE RESORPTION; GENE EXPRESSION REGULATION; GENETIC MARKERS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; OSTEOGENESIS; RATS; WNT SIGNALING PATHWAY;

EID: 84868290353     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2011-1060     Document Type: Review

References (279)

1. Dempster D.W. 2006 Anatomy and function of the adult skeleton. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. Washington, DC: The American Society for Bone and Mineral Research; 7-11
2. Olsen B.R. 2006 Bone embryology. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 6th ed. Washington, DC: The American Society for Bone and Mineral Research; 2-6
3. Bonewald LF. 2011 The amazing osteocyte. J Bone Miner Res 26:229-238
4. Frost HM. 1989 The biology of fracture healing. An overview for clinicians. Part II. Clin Orthop Relat Res 248: 294-309
5. Gerstenfeld LC, Einhorn TA. 2006 Fracture healing: the biology of bone repair and regeneration. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 6th ed. Washington, DC: The American Society for Bone and Mineral Research; 42-48
6. 1993 Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94: 646-650
7. Harvey N, Dennison E, Cooper C. 2008 Epidemiology of osteoporotic fractures. In: Rosen CJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 7th ed. Washington, DC: The American Society for Bone and Mineral Research; 198-202
8. Kawai M, Mödder UI, Khosla S, Rosen CJ. 2011 Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov 10:141-156
9. Rachner TD, Khosla S, Hofbauer LC. 2011 Osteoporosis: now and the future. Lancet 377:1276-1287
10. Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, DaSilva C, Santora AC, Ince BA. 2010 Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 25:937-947
11. Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR, Rizzoli R, Resch H, Verbruggen N, Hustad CM, DaSilva C, Petrovic R, Santora AC, Ince BA, Lombardi A. 2011 Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 26:242-251
12. Court-Brown CM, Koval KJ. 2006 The epidemiology of fractures. In: Bucholz RW, Heckman JD, Court-Brown C, eds. Rockwood and Green's fractures in adults. Philadelphia: Lippincott; 96-143
13. Einhorn TA. 1995 Enhancement of fracture-healing. J Bone Joint Surg Am 77:940-956
14. Einhorn TA. 2003 Clinical applications of recombinant human BMPs: early experience and future development. J Bone Joint Surg Am 85-A(Suppl 3):82-88
15. Garrison KR, Donell S, Ryder J, Shemilt I, Mugford M, Harvey I, Song F. 2007 Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the nonhealing of fractures and spinal fusion: a systematic review. Health Technol Assess 11:1-150, iii-iv
16. Mont MA, Ragland PS, Biggins B, Friedlaender G, Patel T, Cook S, Etienne G, Shimmin A, Kildey R, Rueger DC, Einhorn TA. 2004 Use of bone morphogenetic proteins for musculoskeletal applications. An overview. J Bone Joint Surg Am 86-A(Suppl 2):41-55
17. Baron R, Rawadi G 2007 Minireview: targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148:2635-2643
18. Hoeppner LH, Secreto FJ, Westendorf JJ 2009 Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 13:485-496
19. Johnson ML, Kamel MA. 2007 The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol 19:376-382
20. Paszty C, Turner CH, Robinson MK 2010 Sclerostin: a gem from the genome leads to bone-building antibodies. J Bone Miner Res 25:1897-1904
21. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP 2002 High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513-1521
22. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, et al. 2002 A mutation in the LDL receptorrelated protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11-19
23. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, et al. 2001 LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513-523
24. Babij P, ZhaoW, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, Reddy PS, Bodine PV, Robinson JA, Bhat B, Marzolf J, Moran RA, Bex F. 2003 High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 18:960-974
25. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W. 2001 Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537-543
26. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J 2001 Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68:577-589
27. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, Foernzler D, Van Hul W. 2002 Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 39:91-97
28. Guo J, Liu M, Yang D, Bouxsein ML, Saito H, Galvin RJ, Kuhstoss SA, Thomas CC, Schipani E, Baron R, Bringhurst FR, Kronenberg HM. 2010 Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab 11:161-171
29. Kramer I, Loots GG, Studer A, Keller H, Kneissel M. 2010 Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 25:178-189
30. Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, Shalhoub V, Ominsky MS, Zhu Ke H, Li X, Richards W.G. 2006 Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39:754-766
31. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM 2005 Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 15: 928-935
32. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA 2003 Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267-6276
33. Yao GQ, Wu JJ, Troiano N, Insogna K 2011 Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice. J Bone Miner Metab 29:141-148
34. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C 2008 Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860-869
35. Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X, He L 2009 Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/β-catenin signaling. J Bone Miner Res 24:1651-1661
36. Brommage R, Liu J, Suwanichikul A, Powell DR 2006 High bone mass in sclerostin-deficient knockout mice. J Musculoskelet Neuronal Interact 6:392
37. Morvan F, Boulukos K, Clément-Lacroix P, Roman Roman S, Suc-Royer I, Vayssie're B, Ammann P, Martin P, Pinho S, Pognonec P, Mollat P, Niehrs C, Baron R, Rawadi G. 2006 Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21:934-945
38. MacDonald BT, Joiner DM, Oyserman SM, Sharma P, Goldstein SA, He X, Hauschka PV 2007 Bone mass is inversely proportional to Dkk1 levels in mice. Bone 41:331-339
39. Joiner DM, MacDonald BT, He X, Hauschka PV, Goldstein SA, Bone density increases in mice with genetically lowered expression levels of the Wnt inhibitor DKK1. Proc 53rd Annual Meeting of the Orthopaedic Research Society, San Diego, California, 2007, Poster 1386
40. Chen Y, Whetstone HC, Lin AC, Nadesan P, Wei Q, Poon R, Alman BA 2007 β-Catenin signaling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing. PLoS Med 4:e249
41. Minear S, Leucht P, Jiang J, Liu B, Zeng A, Fuerer C, Nusse R, Helms JA. 2010 Wnt proteins promote bone regeneration. Sci Transl Med 2:29ra30
42. Komatsu DE, Mary MN, Schroeder RJ, Robling AG, Turner CH, Warden SJ 2010 Modulation of Wnt signaling influences fracture repair. J Orthop Res 28:928-936
43. Kim JB, Leucht P, Lam K, Luppen C, Ten Berge D, Nusse R, Helms JA 2007 Bone regeneration is regulated by wnt signaling. J Bone Miner Res 22:1913-1923
44. Bajada S, Marshall MJ, Wright KT, Richardson JB, JohnsonWE. 2009 Decreased osteogenesis, increased cell senescence and elevated Dickkopf-1 secretion in human fracture non union stromal cells. Bone 45:726-735
45. Study of BHQ880 in patients with high risk smoldering multiple myeloma. http://clinicaltrials.gov/ct2/show/NCT01302886?term=nct01302886&rank=1. Accessed on November 5, 2011.
46. Guder C, Philipp I, Lengfeld T, Watanabe H, Hobmayer B, Holstein TW 2006 The Wnt code: cnidarians signal the way. Oncogene 25:7450-7460
47. Lengfeld T, Watanabe H, Simakov O, Lindgens D, Gee L, Law L, Schmidt HA, Ozbek S, Bode H, Holstein T.W. 2009 Multiple Wnts are involved in Hydra organizer formation and regeneration. Dev Biol 330:186-199
48. Srivastava M, Begovic E, Chapman J, Putnam NH, Hellsten U, Kawashima T, Kuo A, Mitros T, Salamov A, Carpenter ML, Signorovitch AY, Moreno MA, Kamm K, Grimwood J, Schmutz J, Shapiro H, Grigoriev IV, Buss LW, Schierwater B, Dellaporta SL, Rokhsar DS 2008 The Trichoplax genome and the nature of placozoans. Nature 454:955-960
49. Augustin R, Franke A, Khalturin K, Kiko R, Siebert S, Hemmrich G, Bosch TCG 2006 Dickkopf related genes are components of the positional value gradient in Hydra. Dev Biol 296:62-70
50. Guder C, Pinho S, Nacak TG, Schmidt HA, Hobmayer B, Niehrs C, Holstein TW 2006 An ancient Wnt-dickkopf antagonism in Hydra. Development 133:901-911
51. Study in patients with untreated multiple myeloma and renal insufficiency. http://clinicaltrials.gov/ct2/show/ NCT01337752?term=nct01337752&rank=1 Accessed on November 5, 2011.
52. Ten Dijke P, Krause C, de Gorter DJ, Lowik CW, van Bezooijen RL 2008 Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am 90(Suppl 1):31-35
53. A study to assess BHQ880 in combination with zoledronic acid in relapsed or refractory myeloma patients. http://clinicaltrials.gov/ct2/show/NCT00741377?term= nct00741377&rank=1 Accessed on November 5, 2011.
54. Ai M, Holmen SL, Van Hul W, Williams BO, WarmanML 2005 Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol 25:4946-4955
55. Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Bénichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warman ML, De Vernejoul MC, Bollerslev J, Van Hul W 2003 Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 72:763-771
56. Pangrazio A, Boudin E, Piters E, Damante G, Lo Iacono N, D'Elia AV, Vezzoni P, Van Hul W, Villa A, Sobacchi C 2011 Identification of the first deletion in the LRP5 gene in a patient with autosomal dominant osteopetrosis type I. Bone 49:568-571
57. Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, Brown A, Gardner JC, Galas D, Schatzman RC, Beighton P, Papapoulos S, Hamersma H, Brunkow ME 2002 A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet 110: 144-152
58. Winkler DG, Sutherland MS, Ojala E, Turcott E, Geoghegan JC, Shpektor D, Skonier JE, Yu C, Latham JA 2005 Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem 280:2498-2502
59. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D 2005 Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883-19887
60. Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, Krumlauf R 2006 Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res 21:1738-1749
61. Semënov M, Tamai K, He X 2005 SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 280:26770-26775
62. Balemans W, Piters E, Cleiren E, Ai M, Van Wesenbeeck L, Warman ML, Van Hul W 2008 The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Calcif Tissue Int 82:445-453
63. Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, Muzylak M, Greenslade K, Moore A, Zhang L, Gong J, Qian X, Paszty C, Taylor RJ, Robinson MK, Carr MD 2009 Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 284:10890-10900
64. Weidauer SE, Schmieder P, Beerbaum M, Schmitz W, Oschkinat H, Mueller TD 2009 NMR structure of the Wnt modulator protein sclerostin. Biochem Biophys Res Commun 380:160-165
65. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C 2009 Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578-588
66. Bourhis E, Tam C, Franke Y, Bazan JF, Ernst J, Hwang J, Costa M, Cochran AG, Hannoush RN 2010 Reconstitution of a Frizzled8.Wnt3a.LRP6 signaling complex reveals multipleWntandDkk1binding sites on LRP6. J BiolChem 285:9172-9179
67. Ettenberg SA, Charlat O, Daley MP, Liu S, Vincent KJ, Stuart DD, Schuller AG, Yuan J, Ospina B, Green J, Yu Q, Walsh R, Li S, Schmitz R, Heine H, Bilic S, Ostrom L, Mosher R, Hartlepp KF, Zhu Z, Fawell S, Yao YM, Stover D, Finan PM, Porter JA, Sellers WR, Klagge IM, Cong F 2010 Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc Natl Acad Sci USA 107: 15473-15478
68. Gong Y, Bourhis E, Chiu C, Stawicki S, DeAlmeida VI, LiuBY, Phamluong K, Cao TC, Carano RA, Ernst JA, Solloway M, Rubinfeld B, Hannoush RN, Wu Y, Polakis P, Costa M 2010 Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies. PLoS One 5:e12682
69. Cheng Z, Biechele T, Wei Z, Morrone S, Moon RT, Wang L, Xu W 2011 Crystal structures of the extracellular domain of LRP6 and its complex with DKK1. Nat Struct Mol Biol 18:1204-1210
70. Bourhis E, Wang W, Tam C, Hwang J, Zhang Y, Spittler D, Huang OW, Gong Y, Estevez A, Zilberleyb I, Rouge L, Chiu C, Wu Y, Costa M, Hannoush RN, Franke Y, Cochran AG 2011Wntantagonists bind through a short peptide to the first β-propeller domain of LRP5/6. Structure 19: 1433-1442
71. Liu S, Virdi AS, Sena K, Sumner DR Sclerostin antibody prevents polyethylene particle-induced implant loosening in a rat model. Transactions of the 57th Annual Orthopaedic Research Society Meeting, Long Beach, CA, 2011: Poster 1050
72. Choi HY, Dieckmann M, Herz J, Niemeier A 2009 Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS One 4:e7930
73. Johnson EB, Hammer RE, Herz J 2005 Abnormal development of the apical ectodermal ridge and polysyndactyly in Megf7-deficient mice. Hum Mol Genet 14:3523-3538
74. Simon-Chazottes D, Tutois S, Kuehn M, Evans M, Bourgade F, Cook S, Davisson MT, Guénet JL 2006 Mutations in the gene encoding the low-density lipoprotein receptor LRP4 cause abnormal limb development in the mouse. Genomics 87:673-677
75. Duchesne A, Gautier M, Chadi S, Grohs C, Floriot S, Gallard Y, Caste G, Ducos A, Eggen A 2006 Identification of a doublet missense substitution in the bovine LRP4 gene as a candidate causal mutation for syndactyly in Holstein cattle. Genomics 88:610-621
76. Johnson EB, Steffen DJ, Lynch KW, Herz J 2006 Defective splicing of Megf7/Lrp4, a regulator of distal limb development, in autosomal recessive mulefoot disease. Genomics 88:600-609
77. Li Y, Pawlik B, Elcioglu N, Aglan M, Kayserili H, Yigit G, Percin F, Goodman F, Nürnberg G, Cenani A, Urquhart J, Chung BD, Ismail S, Amr K, Aslanger AD, Becker C, Netzer C, Scambler P, Eyaid W, Hamamy H, Clayton-Smith J, Hennekam R, Nürnberg P, Herz J, Temtamy SA, Wollnik B 2010 LRP4 mutations alter Wnt/β-catenin signaling and cause limb and kidney malformations in Cenani-Lenz syndrome. Am J Hum Genet 86:696-706
78. Leupin O, Piters E, Halleux C, Hu S, Kramer I, Morvan F, Bouwmeester T, Schirle M, Bueno-Lozano M, Fuentes FJ, Itin PH, Boudin E, de Freitas F, Jennes K, Brannetti B, Charara N, Ebersbach H, Geisse S, Lu CX, Bauer A, Van Hul W, Kneissel M 2011 Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem 286:19489-19500
79. Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, Delius H, Hoppe D, Stannek P, Walter C, Glinka A, Niehrs C 2002 Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling. Nature 417:664-667
80. Ellwanger K, Saito H, Clément-Lacroix P, Maltry N, Niedermeyer J, Lee WK, Baron R, Rawadi G, Westphal H, Niehrs C 2008 Targeted disruption of the Wnt regulator Kremen induces limb defects and high bone density. Mol Cell Biol 28:4875-4882
81. Schulze J, Seitz S, Saito H, Schneebauer M, Marshall RP, Baranowsky A, Busse B, Schilling AF, Friedrich FW, Albers J, Spiro AS, Zustin J, Streichert T, Ellwanger K, Niehrs C, Amling M, Baron R, Schinke T 2010 Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2. PLoS ONE 5:e10309
82. Collette NM, Genetos DC, Murugesh D, Harland RM, Loots GG 2010 Genetic evidence that SOST inhibitsWNT signaling in the limb. Dev Biol 342:169-179
83. Mukhopadhyay M, Shtrom S, Rodriguez-Esteban C, Chen L, Tsukui T, Gomer L, Dorward DW, Glinka A, Grinberg A, Huang SP, Niehrs C, Izpisúa Belmonte JC, Westphal H 2001 Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Dev Cell 1:423-434
84. Adamska M, MacDonald BT, Sarmast ZH, Oliver ER, Meisler MH 2004 En1 and Wnt7a interact with Dkk1 during limb development in the mouse. Dev Biol 272:134-144
85. MacDonald BT, Adamska M, Meisler MH 2004 Hypomorphic expression of Dkk1 in the doubleridge mouse: dose dependence and compensatory interactions with Lrp6. Development 131:2543-2552
86. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CW, Reeve J 2005 Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842-1844
87. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CW 2004 Sclerostin is an osteocyteexpressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199:805-814
88. Didangelos A, Yin X, Mandal K, Baumert M, Jahangiri M, Mayr M 2010 Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics 9:2048-2062
89. van Bezooijen RL, Deruiter MC, Vilain N, Monteiro RM, Visser A, van der Wee-Pals L, van Munsteren CJ, Hogendoorn PC, Aguet M, Mummery CL, Papapoulos SE, Ten Dijke P, Löwik CW 2007 SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development. Dev Dyn 236:606-612
90. Zhu D, Mackenzie NC, Millán JL, Farquharson C, Mac-Rae VE 2011 The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 6:e19595
91. Chan BY, Fuller ES, Russell AK, Smith SM, Smith MM, Jackson MT, Cake MA, Read RA, Bateman JF, Sambrook PN, Little CB 2011 Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis. Osteoarthritis Cartilage 19:874-885
92. Fedi P, Bafico A, Nieto Soria A, Burgess WH, Miki T, Bottaro DP, Kraus MH, Aaronson SA 1999 Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalianWntsignaling. J Biol Chem 274:19465-19472
93. Krupnik VE, Sharp JD, Jiang C, Robison K, Chickering TW, Amaravadi L, Brown DE, Guyot D, Mays G, Leiby K, Chang B, Duong T, Goodearl AD, Gearing DP, Sokol SY, McCarthy SA 1999 Functional and structural diversity of the human Dickkopf gene family. Gene 238:301-313
94. Ueland T, Otterdal K, Lekva T, Halvorsen B, Gabrielsen A, Sandberg WJ, Paulsson-Berne G, Pedersen TM, Folkersen L, Gullestad L, Oie E, Hansson GK, Aukrust P 2009 Dickkopf-1 enhances inflammatory interaction between platelets and endothelial cells and shows increased expression in atherosclerosis. Arterioscler Thromb Vasc Biol 29: 1228-1234
95. Yamaguchi Y, Passeron T, Hoashi T, Watabe H, Rouzaud F, Yasumoto K, Hara T, Tohyama C, Katayama I, Miki T, Hearing VJ 2008 Dickkopf 1 (DKK1) regulates skin pigmentation and thickness by affecting Wnt/β-catenin signaling in keratinocytes. FASEB J 22:1009-1020
96. Cheng SL, Towler D Msx2-Wnt signaling inhibits and Dkk1 promotes the endothelial-mesenchymal transition in primary aortic endothelial cells. Proc 33rd Annual Meeting of the American Society for Bone and Mineral Research, San Diego, CA, 2011, p S41 (Abstract 1118)
97. Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH 2011 Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res 26:2812-2822
98. Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton 3rd LJ, Khosla S 2011 Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 26:373-379
99. Amrein K, Amrein S, Drexler C, Dimai H, Pieber TR, Tomaschitz A, Dobnig H Sclerostin is associated with age, BMI, and bone mineral content, but not gender or physical activity in healthy adults. Proc 33rd Annual Meeting of the American Society for Bone and Mineral Research, San Diego, CA, 2011, p S338 (Abstract SU0346)
100. Jemtland R, Holden M, Reppe S, Olstad OK, Reinholt FP, Gautvik VT, Refvem H, Frigessi A, Houston B, Gautvik KM 2011 Molecular disease map of bone characterizing the postmenopausal osteoporosis phenotype. J Bone Miner Res 26:1793-1801
101. Li X, Grisanti M, Fan W, Asuncion FJ, Tan HL, Dwyer D, Han CY, Yu L, Lee J, Lee E, Barrero M, Kurimoto P, Niu QT, Geng Z, Winters A, Horan T, Steavenson S, Jacobsen F, Chen Q, Haldankar R, Lavallee J, Tipton B, Daris M, Sheng J, Lu HS, Daris K, Deshpande R, Valente EG, Salimi-Moosavi H, Kostenuik PJ, Li J, Liu M, Li C, Lacey DL, Simonet WS, Ke HZ, Babij P, Stolina M, Ominsky MS, Richards WG 2011 Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. J Bone Miner Res 26:2610-2621
102. Butler JS, Murray DW, Hurson CJ, O'Brien J, Doran PP, O'Byrne JM 2011 The role of Dkk1 in bone mass regulation: correlating serum Dkk1 expression with bone mineral density. J Orthop Res 29:414-418
103. Sutherland MK, Geoghegan JC, Yu C, Winkler DG, Latham JA 2004 Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone 35:448-454
104. Genetos DC, Toupadakis CA, Raheja LF, Wong A, Papanicolaou SE, Fyhrie DP, Loots GG, Yellowley CE 2010 Hypoxia decreases sclerostin expression and increasesWnt signaling in osteoblasts. J Cell Biochem 110:457-467
105. Kamiya N, Kobayashi T, Mochida Y, Yu PB, Yamauchi M, Kronenberg HM, Mishina Y 2010 Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. J Bone Miner Res 25:200-210
106. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA 2010 Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95:1991-1997
107. Mödder UI, Roforth MM, Hoey K, McCready LK, Peterson JM, Monroe DG, Oursler MJ, Khosla S 2011 Effects of estrogen on osteoprogenitor cells and cytokines/boneregulatory factors in postmenopausal women. Bone 49: 202-207
108. Mödder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S 2011 Regulation of circulating sclerostin levels by sex steroids inwomenand in men. J Bone Miner Res 26:27-34
109. Jastrzebski S, Kalinowski J, Fei Y, Choudhary S, Pilbeam C, Mirza F, Hurley MM, Lorenzo J Sclerostin production decreases after ovariectomy in mouse bones in association with an increase in bone formation. Proc 33rd Annual Meeting of the American Society for Bone and Mineral Research, San Diego, CA, 2011, p S498 (Abstract MO0400)
110. Keller H, Kneissel M 2005 SOST is a target gene for PTH in bone. Bone 37:148-158
111. Silvestrini G, Ballanti P, Leopizzi M, Sebastiani M, Berni S, Di Vito M, Bonucci E 2007 Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol 38:261-269
112. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL 2005 Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577-4583
113. Gatti D, Viapiana O, Idolazzi L, Fracassi E, Rossini M, Adami S 2011 The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab 96:1555-1559
114. Drake MT, Srinivasan B, Mödder UI, Peterson JM, Mc-Cready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S 2010 Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95:5056-5062
115. Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche HH 2011 Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 6:877-882
116. Anastasilakis AD, Polyzos SA, Avramidis A, Toulis KA, Papatheodorou A, Terpos E 2010 The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. Clin Endocrinol (Oxf) 72: 752-757
117. Canalis E, Mazziotti G, Giustina A, Bilezikian JP 2007 Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319-1328
118. Ohnaka K, Taniguchi H, Kawate H, Nawata H, Takayanagi R 2004 Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism ofglucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 318:259-264
119. Butler JS, Queally JM, Devitt BM, MurrayDW, Doran PP, O'Byrne JM 2010 SilencingDkk1expression rescues dexamethasone-induced suppression of primary human osteoblast differentiation. BMC Musculoskelet Disord 11:210
120. Yao W, Cheng Z, Pham A, Busse C, Zimmermann EA, Ritchie RO, Lane NE 2008 Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum 58:3485-3497
121. Gossiel F, Lane N, Eastell R The effect of glucocorticoid therapy on regulators of bone formation in postmenopausal women treated with teriparatide or alendronate. Proc 33rd Annual Meeting of the American Society for Bone and Mineral Research, San Diego, CA, 2011, p S80 (Abstract 1252)
122. Weinstein RS, Nicholas RW, Manolagas SC 2000 Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 85:2907-2912
123. Ko JY, Wang FS, Wang CJ, Wong T, Chou WY, Tseng SL 2010 Increased Dickkopf-1 expression accelerates bone cell apoptosis in femoral head osteonecrosis. Bone 46: 584-591
124. Genetos DC, Yellowley CE, Loots GG 2011 Prostaglandin E2 signals through PTGER2 to regulate sclerostin expression. PLoS One 6:e17772
125. FindlayDM, Atkins GJ 2011TWEAKandTNFregulation of sclerostin: a novel pathway for the regulation of bone remodelling. Adv Exp Med Biol 691:337-348
126. Vincent C, Findlay DM, Welldon KJ, Wijenayaka AR, Zheng TS, Haynes DR, Fazzalari NL, Evdokiou A, Atkins GJ 2009 Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFα induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res 24:1434-1449
127. Atkins GJ, Welldon KJ, Holding CA, Haynes DR, Howie DW, Findlay DM 2009 The induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene particles. Biomaterials 30:3672-3681
128. Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, Haibel H, Baraliakos X, Hempfing A, Rudwaleit M, Sieper J, Schett G 2009 Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 60:3257-3262
129. Wehmeyer C, Stratis A, Pap T, Dankbar B 2010 The role of the wnt inhibitor sclerostin in rheumatoid arthritis. Ann Rheum Dis 69:A21
130. Lane NE, NevittMC, Lui LY, de Leon P, Corr M 2007Wnt signaling antagonists are potential prognostic biomarkers for the progression of radiographic hip osteoarthritis in elderly Caucasian women. Arthritis Rheum 56:3319-3325
131. Schett G 2007 Joint remodeling in inflammatory disease. Ann Rheum Dis 66:42-44
132. Schett G, Zwerina J, David JP 2008. The role of Wnt proteins in arthritis. Nat Clin Pract Rheumatol 4:473-480
133. Walsh NC, Gravallese EM 2010 Bone remodeling in rheumatic disease: a question of balance. Immunol Rev 233: 301-312
134. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G 2007 Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156-163
135. Garcia-Martin A, Rozas-Moreno P, Morales-Santana S, Garcia-Fontana B, Garcia-Salcedo JA, Reyes R, Munoz-Torres M Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. Proc 33rd Annual Meeting of the American Society for Bone and Mineral Research, San Diego, CA, 2011, p S142 (Abstract SA0407)
136. Hie M, Iitsuka N, Otsuka T, Tsukamoto I 2011 Insulindependent diabetes mellitus decreases osteoblastogenesis associated with the inhibition of Wnt signaling through increased expression of Sost and Dkk1 and inhibition of Akt activation. Int J Mol Med 28:455-462
137. Portal-Núñ ez S, Lozano D, de Castro LF, de Gortázar AR, Nogués X, Esbrit P 2010 Alterations of the Wnt/β-catenin pathway and its target genes for the N- and C-terminal domains of parathyroid hormone-related protein in bone from diabetic mice. FEBS Lett 584:3095-3100
138. van Lierop AH, Hamdy NA, van der Meer R, Jonker J, Diamant M, Rijzewijk L, de Roos A, Romijn J, Smit J, Papapoulos S Effects of pioglitazone on serum levels of sclerostin and bone turnover markers in male patients with type 2 diabetes mellitus. Proc 33rd Annual Meeting of the American Society for Bone and Mineral Research, San Diego, CA, 2011, p S469 (Abstract MO0309)
139. Gustafson B, Eliasson B, Smith U 2010 Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis. Diabetologia 53:536-540
140. Nuche-Berenguer B, Moreno P, Portal-Nuñez S, Dapía S, Esbrit P, Villanueva-Peñ acarrillo ML 2010 Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regul Pept 159:61-66
141. Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, Rosol TJ, Shaughnessy Jr JD 2009 The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 113:517-525
142. Dimopoulos MA, Terpos E 2010 Multiple myeloma. Ann Oncol 21(Suppl 7):vii143-vii150
143. Edwards CM, Zhuang J, Mundy GR 2008 The pathogenesis of the bone disease of multiple myeloma. Bone 42: 1007-1013
144. Terpos E, Dimopoulos MA 2005 Myeloma bone disease: pathophysiology and management. Ann Oncol 16:1223-1231
145. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy Jr JD 2003 The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483-2494
146. Haaber J, Abildgaard N, Knudsen LM, Dahl IM, Lodahl M, Thomassen M, Kerndrup GB, Rasmussen T 2008 Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis. Br J Haematol 140:25-35
147. Heider U, Kaiser M, Mieth M, Lamottke B, RademacherJ, Jakob C, Braendle E, Stover D, Sezer O 2009 Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol 82:31-38
148. Kaiser M, Mieth M, Liebisch P, Oberländer R, Rademacher J, Jakob C, Kleeberg L, Fleissner C, Braendle E, Peters M, Stover D, Sezer O, Heider U 2008 Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 80: 490-494
149. Lemaire O, Attal M, Bourin P, Laroche M 2010 DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma. Eur J Haematol 84:276-277
150. Politou MC, Heath DJ, Rahemtulla A, Szydlo R, Anagnostopoulos A, Dimopoulos MA, Croucher PI, Terpos E 2006 Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 119:1728-1731
151. Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI 2006 Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 135:688-692
152. Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J, Barlogie B, Shaughnessy Jr JD 2008 Myelomaderived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 112:196-207
153. Terpos E, Christoulas D, Katodritou E, Bratengeier C, Gkotzamanidou M, Michalis E, Delimpasi S, Pouli A, Meletis J, Kastritis E, Zervas K, DimopoulosMA 2 November 2011 Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. Int J Cancer doi: 10.1002/ijc.27342
154. van Bezooijen RL, ten Dijke P, Papapoulos SE, Löwik CW 2005 SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16:319-327
155. Irie K, Ejiri S, Sakakura Y, Shibui T, Yajima T 2008 Matrix mineralization as a trigger for osteocyte maturation. J Histochem Cytochem 56:561-567
156. Atkins GJ, Rowe PS, Lim HP, Welldon KJ, Ormsby R, Wijenayaka AR, Zelenchuk L, Evdokiou A, Findlay DM 2011 Sclerostin is a locally acting regulator of late-osteoblast/ pre-osteocyte differentiation and regulates mineralization through a MEPE-ASARM dependent mechanism. J Bone Miner Res 26:1425-1436
157. Frost HM 1987 Bone "mass" and the "mechanostat": a proposal. Anat Rec 219:1-9
158. Price JS, Sugiyama T, Galea GL, Meakin LB, Sunters A, Lanyon LE 2011 Role of endocrine and paracrine factors in the adaptation of bone to mechanical loading. Curr Osteoporos Rep 9:76-82
159. Hens JR, Wilson KM, Dann P, Chen X, Horowitz MC, Wysolmerski JJ 2005 TOPGAL mice show that the canonical Wnt signaling pathway is active during bone development and growth and is activated by mechanical loading in vitro. J Bone Miner Res 20:1103-1113
160. Kiel DP, Ferrari SL, Cupples LA, Karasik D, Manen D, Imamovic A, Herbert AG, Dupuis J 2007 Genetic variation at the low-density lipoprotein receptor-related protein 5 (LRP5) locus modulatesWntsignaling and the relationship of physical activity with bone mineral density in men. Bone 40:587-596
161. Kim-Weroha NA, Ferris A, Holladay B, Kotha SP, Kamel MA, Johnson ML In vivo load activated propagation of B-catenin signaling in osteocytes through coordinated downregulation of inhibitors of Lrp5. Proc 30th Annual Meeting of the American Society for Bone and Mineral Research, Montreal, Quebec, Canada, 2008, p S13 (Abstract 1041)
162. Sawakami K, Robling AG, Ai M, Pitner ND, Liu D, Warden SJ, Li J, Maye P, RoweDW, Duncan RL, Warman ML, Turner CH 2006 TheWntco-receptorLRP5is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem 281:23698-23711
163. Saxon LK, Jackson BF, Sugiyama T, Lanyon LE, Price JS 2011 Analysis of multiple bone responses to graded strains above functional levels, and to disuse, in mice in vivo show that the human Lrp5 G171V high bone mass mutation increases the osteogenic response to loading but that lack of Lrp5 activity reduces it. Bone 49:184-193
164. Bonewald LF, Johnson ML 2008 Osteocytes, mechanosensing and Wnt signaling. Bone 42:606-615
165. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH 2008 Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/ sclerostin. J Biol Chem 283:5866-5875
166. Zhao N Sost/sclerostin expression in alveolar osteocytes during orthodontic tooth movement. Proc Second Meeting of International Association for Dental Research (IADR) Pan Asian Pacific Federation (PAPF) and the First Meeting of IADR Asia/Pacific Region (APR), Wuhan, China, 2009 (Abstract 0438)
167. Papanicolaou SE, Phipps RJ, Fyhrie DP, Genetos DC 2009 Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells. Biorheology 46:389-399
168. Spatz JM, Ellman R, CloutierAM, Dwyer D, StolinaM, Ke HZ, Bouxsein M Treatment with sclerostin antibody increases bone mass and strength during hindlimb unloading. Proc 33rd Annual Meeting of the American Society for Bone and Mineral Research, San Diego, CA, 2011, p S24 (Abstract 1069)
169. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, HawaG, Tringali G, Fiore CE 2010 Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 95:2248-2253
170. van Oers RF, van Rietbergen B, Ito K, Hilbers PA, Huiskes R 2011 A sclerostin-based theory for strain-induced bone formation. Biomech Model Mechanobiol 10:663-670
171. BurgessAW, FauxMC, Layton MJ, Ramsay RG 2011Wntsignaling and colon tumorigenesis-a view from the periphery. Exp Cell Res 317:2748-2758
172. Clevers H 2006 Wnt/β-catenin signaling in development and disease. Cell 127:469-480
173. Lucero OM, Dawson DW, Moon RT, Chien AJ 2010 A re-evaluation of the "oncogenic" nature of Wnt/β-catenin signaling in melanoma and other cancers. Curr Oncol Rep 12:314-318
174. Polakis P 2007 The many ways of Wnt in cancer. Curr Opin Genet Dev 17:45-51
175. van Ooyen A, Nusse R 1984 Structure and nucleotide sequence of the putative mammary oncogene int-1; proviral insertions leave the protein-encoding domain intact. Cell 39:233-240
176. Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, WoenckhausM, Kristiansen G, Hsieh JC, Hofstaedter F, Hartmann A, Knuechel R, Rosenthal A, Pilarsky C 2003 WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 201: 204-212
177. Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, EhrichM, Dobrovic A, Slavin J, Choong PF, Simmons PJ, Dawid IB, Thomas DM 2009 Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 119:837-851
178. Hirata H, Hinoda Y, Nakajima K, Kawamoto K, Kikuno N, Ueno K, Yamamura S, Zaman MS, Khatri G, Chen Y, Saini S, Majid S, Deng G, Ishii N, Dahiya R 2011 Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int J Cancer 128:1793-1803
179. Yu B, Yang X, Xu Y, Yao G, Shu H, Lin B, Hood L, Wang H, Yang S, Gu J, Fan J, Qin W 2009 Elevated expression of DKK1 is associated with cytoplasmic/nuclear β-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol 50:948-957
180. Takahashi N, Fukushima T, Yorita K, Tanaka H, Chijiiwa K, Kataoka H 2010 Dickkopf-1 is overexpressed in human pancreatic ductal adenocarcinoma cells and is involved in invasive growth. Int J Cancer 126:1611-1620
181. Sato N, Yamabuki T, Takano A, Koinuma J, Aragaki M, Masuda K, Ishikawa N, Kohno N, Ito H, Miyamoto M, Nakayama H, Miyagi Y, Tsuchiya E, Kondo S, Nakamura Y, Daigo Y 2010 Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res 70:5326-5336
182. Qian J, Zheng Y, Zheng C, Wang L, Qin H, Hong S, Li H, Lu Y, He J, Yang J, Neelapu S, Kwak LW, Hou J, Yi Q 2012 Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood 119:161-169
183. Menezes ME, Devine DJ, Shevde LA, Samant RS 2012 Dickkopf1: a tumor suppressor or metastasis promoter? Int J Cancer 130:1477-1483
184. Beighton P, Durr L, Hamersma H 1976 The clinical features of sclerosteosis. A review of the manifestations in twenty-five affected individuals. Ann Intern Med 84:393-397
185. Beighton P, Cremin BJ, Hamersma H 1976 The radiology of sclerosteosis. Br J Radiol 49:934-939
186. Hamersma H, Gardner J, Beighton P 2003 The natural history of sclerosteosis. Clin Genet 63:192-197
187. van Bezooijen RL, Bronckers AL, Gortzak RA, Hogendoorn PC, van der Wee-Pals L, Balemans W, Oostenbroek HJ, Van Hul W, Hamersma H, Dikkers FG, Hamdy NA, Papapoulos SE, Löwik CW 2009 Sclerostin in mineralized matrices and van Buchem disease. J Dent Res 88:569-574
188. Epstein S, Hamersma H, Beighton P 1979 Endocrine function in sclerosteosis. S Afr Med J 55:1105-1110
189. van Lierop AH, Hamdy NA, Hamersma H, van Bezooijen RL, Power J, Loveridge N, Papapoulos SE 2011 Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res 26:2804-2811
190. Stein SA, Witkop C, Hill S, FallonMD, Viernstein L, Gucer G, McKeever P, Long D, Altman J, Miller NR, Teitelbaum SL, Schlesinger S 1983 Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship. Neurology 33:267-277
191. Gardner JC, van Bezooijen RL, Mervis B, Hamdy NA, Löwik CW, Hamersma H, Beighton P, Papapoulos SE 2005 Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab 90: 6392-6395
192. Wergedal JE, Veskovic K, Hellan M, Nyght C, Balemans W, Libanati C, Vanhoenacker FM, Tan J, Baylink DJ, Van Hul W 2003 Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab 88:5778-5783
193. Huang QY, Li GH, Kung AW 2009 The-9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPα and FOXA1 binding is associated with osteoporosis. Bone 45:289-294
194. Uitterlinden AG, Arp PP, Paeper BW, Charmley P, Proll S, Rivadeneira F, Fang Y, van Meurs JB, Britschgi TB, Latham JA, Schatzman RC, Pols HA, Brunkow ME 2004 Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites. Am J Hum Genet 75:1032-1045
195. Yerges LM, Klei L, Cauley JA, Roeder K, Kammerer CM, Moffett SP, Ensrud KE, Nestlerode CS, Marshall LM, Hoffman AR, Lewis C, Lang TF, Barrett-Connor E, Ferrell RE, Orwoll ES, Zmuda JM 2009 High-density association study of 383 candidate genes for volumetric BMD at the femoral neck and lumbar spine among older men. J Bone Miner Res 24:2039-2049
196. Harland R, Murugesh D, Loots G, Yee C, Collette N Increased WNT signaling in Sclerostin/Sostdc1 double knockouts causes preaxial polydactyly. Proc 33rd Annual Meeting of the American Society for Bone and Mineral Research, San Diego, CA, 2011, p S117 (Abstract FR0208)
197. Krause C, Korchynskyi O, de Rooij K, Weidauer SE, de Gorter DJ, van Bezooijen RL, Hatsell S, Economides AN, Mueller TD, Löwik CW, ten Dijke P 2010 Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 285:41614-41626
198. Liu M, Kurimoto P, Niu QT, Ke HZ Effect of estrogen deficiency in sclerostin knockout mice. Proc 33rd AnnualMeeting of the American Society for Bone and Mineral Research, San Diego, CA, 2011, p S234 (Abstract SA0461)
199. Eddleston A, Marenzana M, Moore AR, Stephens P, Muzylak M, Marshall D, Robinson MK 2009 A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res 24: 1662-1671
200. Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M, Ominsky MS, Kostenuik PJ, Simonet WS, Paszty C, KeHZ 2010 Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 25:2647-2656
201. Tian X, Jee WS, Li X, Paszty C, Ke HZ 2011 Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone 48:197-201
202. MarenzanaM, Greenslade K, Eddleston A, Okoye R, Marshall D, Moore A, Robinson MK 2011 Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum 63:2385-2395
203. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K, Tipton B, Cai J, Deshpande R, Zhou L, Hale MD, Lightwood DJ, Henry AJ, Popplewell AG, Moore AR, Robinson MK, Lacey DL, Simonet WS, Paszty C 2010 Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 25:948-959
204. Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, DwyerD, HanCY, Vlasseros F, SamadfamR, Jolette J, Smith SY, Stolina M, Lacey DL, Simonet WS, Paszty C, Li G, Ke HZ 2011 Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 26:1012-1021
205. Padhi D, Jang G, Stouch B, Fang L, Posvar E 2011 Singledose, placebo-controlled, randomized study ofAMG785, a sclerostin monoclonal antibody. J Bone Miner Res 26: 19-26
206. Li X, Warmington KS, Niu Q-T, Grisanti M, Tan HL, Simonet WS, Kostenuik PJ, Paszty C, Ke HZ Treatment with an anti-sclerostin antibody directly stimulates bone formation in a dose-dependent manner in ovariectomized rats with established osteopenia. Proc 29th Annual Meeting of the American Society for Bone and Mineral Research, Honolulu, HI, 2007, p S65 (Abstract 1122)
207. Li X, Warmington KS, Xia X, Williams AA, Grisanti M, Niu QT, Dwyer D, Stolina M, Paszty C, Wronski TJ, Ke HZ Sclerostin antibody prevents bone loss and increases bone formation in female rats with high turnover due to ovariectomy. Proc 33rd Annual Meeting of the American Society for Bone and Mineral Research, San Diego, CA, 2011, p S68 (Abstract 1208)
208. Li X, Warmington K, Niu QT, Asuncion F, BarreroM, Xia X, Grisanti M, Lee E, Wronski TJ, Ominsky MS, Simonet WS, Paszty C, Ke HZ Sclerostin inhibition by monoclonal antibody reversed trabecular and cortical bone loss in orchiectomized rats with established osteopenia. Proc 32nd Annual Meeting of the American Society for Bone and Mineral Research, Toronto, Ontario, Canada, 2010, p S80 (Abstract 1261)
209. Robling A, Warden S, Paszty C, Turner C Sclerostin Antibody Protects the Skeleton from Disuse-induced Bone Loss. Proc 32nd Annual Meeting of the American Society for Bone and Mineral Research, Toronto, Ontario, Canada, 2010, p S13 (Abstract 1039)
210. Hamann C, Hohna Y, Rauner M, Goettsch C, Gunther K, Ominsky M, Hofbauer LC Sclerostin inhibition prevents low bone mass associated with type 2 diabetes mellitus in rats. Proc 33rd Annual Meeting of the American Society for Bone and Mineral Research, San Diego, CA, 2011, p S67 (Abstract 1207)
211. Engelbert RH, Pruijs HE, Beemer FA, Helders PJ 1998 Osteogenesis imperfecta in childhood: treatment strategies. Arch Phys Med Rehabil 79:1590-1594
212. Ward LM, Rauch F, Whyte MP, D'Astous J, Gates PE, Grogan D, Lester EL, McCall RE, Pressly TA, Sanders JO, Smith PA, Steiner RD, Sullivan E, Tyerman G, Smith-Wright DL, Verbruggen N, Heyden N, Lombardi A, Glorieux FH 2011 Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab 96:355-364
213. Sinder BP, Eddy MM, Caird MS, Marini JC, Kozloff KM Sclerostin antibody improves skeletal parameters in Brtl/+ model of osteogenesis imperfecta. Transactions of the 57th Annual Orthopaedic Research Society Meeting, Long Beach, CA, 2011 Poster 2284
214. Sinder BP, White LE, Caird MS, Marini JC, Kozloff KM Sclerostin antibody improves bone mass and mechanical properties in an adult Brtl/+ model of osteogenesis imperfecta. Proc 33rd Annual Meeting of the American Society for Bone and Mineral Research, San Diego, CA, 2011, p S61 (Abstract 1185)
215. Behets C, AmmannP, OminskyMS, Coppin C, Devogelaer JP, Manicourt DH Sclerostin antibody increased bone mass and reduced fractures in osteogenesis imperfecta mice. Proc 33rd Annual Meeting of the American Society for Bone and Mineral Research, San Diego, CA, 2011, p S25 (Abstract 1070)
216. Tian X, Setterberg RB, Li X, Paszty C, KeHZ, Jee WS 2010 Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone 47:529-533
217. Ominsky MS, Samadfam R, Jolette J, Vlasseros F, Smith SY, Kostenuik P, Paszty C, Simonet WS, Ke HZ Sclerostin monoclonal antibody stimulates bone formation and improves the strength and density of the fracture callus and lumbar spine in a primate fibular osteotomy model. Proc 31st Annual Meeting of the American Society for Bone and Mineral Research, Denver, CO, 2009, p S89-90 (Abstract 1290)
218. Li X, Ominsky MS, Warmington KS, Niu QT, Asuncion FJ, BarreroM, Dwyer D, GrisantiM, StolinaM, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ 2011 Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology 152:3312-3322
219. Shahnazari M, Chu V, Stolina M, Wronski TJ, Ke HZ, Halloran B Treatment of skeletally unloaded mice withsclerostin antibody increases osteoblast activity and mineralization. Proc 33rd Annual Meeting of the American Society for Bone and Mineral Research, San Diego, CA, 2011, p S317 (Abstract SU0267)
220. Fox J, Miller MA, Newman MK, Recker RR, Turner CH, Smith SY 2007 Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys. Bone 41:321-330
221. Turner CH, Burr DB, Hock JM, Brommage R, Sato M 2001 The effects of PTH (1-34) on bone structure and strength in ovariectomized monkeys. Adv Exp Med Biol 496:165-179
222. Stolina M, Dwyer D, Niu QT, Li X, Warmington K Treatment with a sclerostin antibody increased osteoblast-derived markers of bone formation and decreased osteoclast-related markers of bone resorption in ovariectomized rats. Proc 32nd Annual Meeting of the American Society for Bone and Mineral Research, Toronto, Ontario, Canada, 2010, p S346 (Abstract SU0424)
223. Glass 2nd DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G 2005 Canonical wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751-764
224. Holmen SL, Giambernardi TA, Zylstra CR, Buckner-Berghuis BD, Resau JH, Hess JF, Glatt V, Bouxsein ML, Ai M, Warman ML, Williams BO 2004 Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res 19:2033-2040
225. Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL, Williams BO 2005 Essential role of β-catenin in postnatal bone acquisition. J Biol Chem 280:21162-21168
226. Wei W, Zeve D, Suh JM, Wang X, Du Y, Zerwekh JE, Dechow PC, Graff JM, Wan Y 2011 Biphasic and dosagedependent regulation of osteoclastogenesis by β-catenin. Mol Cell Biol 31:4706-4719
227. Erben RG 1996 Trabecular and endocortical bone surfaces in the rat: modeling or remodeling? Anat Rec 246:39-46
228. Lindsay R, Cosman F, Zhou H, Bostrom MP, Shen VW, Cruz JD, Nieves JW, Dempster DW 2006 A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 21:366-373
229. Ominsky MS, Niu QT, Kurimoto P, Ke HZ 2010 Tissue level mechanism of increased bone formation by sclerostin antibody in male cynomolgus monkeys. J Bone Miner Res 25:S52
230. Smith CB, Smith DA 1976 Relations between age, mineral density, and mechanical properties of human femoral compacta. Acta Orthop Scand 47:496-502
231. Smith SY, Jolette J, Turner CH 2009 Skeletal health: primate model of postmenopausal osteoporosis. Am J Primatol 71:752-765
232. Hernandez CJ, Keaveny TM 2006 A biomechanical perspective on bone quality. Bone 39:1173-1181
233. Ominsky MS, Warmington KS, Asuncion FJ, Tan HL, Grisanti M, Geng Z, Stephens P, Henry AJ, Lawson A, Lightwood DJ, Perkins V, Kirby H, Moore AR, Robinson MK, Li X, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C Sclerostin monoclonal antibody treatment increases bone strength in aged osteopenic ovariectomized rats. Proc 28th Annual Meeting of the American Society for Bone and Mineral Research, Philadelphia, PA, 2006, p S44 (Abstract 1161)
234. van Lenthe GH, Voide R, Boyd SK, Müller R 2008 Tissue modulus calculated from beam theory is biased by bone size and geometry: implications for the use of three-point bending tests to determine bone tissue modulus. Bone 43: 717-723
235. Edwards L, Virdi A, Sena K, Sumner DR Assessment of bone mineralization in rats treated with sclerostin antibody. Proc 32nd Annual Meeting of the American Society for Bone and Mineral Research, Toronto, Ontario, Canada, 2010, p S150-S151 (Abstract SA0066)
236. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215
237. Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV 2008 Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852-860
238. Boonen S, Milisen K, Gielen E, Vanderschueren D 2011 Sequential therapy in the treatment of osteoporosis. Curr Med Res Opin 27:1149-1155
239. Lindsay R, Cosman F, Zhou H, Bostrom MP, Nieves J, Dempster D. Early bone formation response to teriparatide (TPTD) in subjects pre-treated with alendronate or risedronate compared to treatment-naive subjects. Proc 31st Annual Meeting of the American Society for Bone and Mineral Research, Denver, CO, 2009, p S21 (Abstract SA0347)
240. Kim SW, Pajevic PD, Selig M, Kronenberg H Intermittent PTH of short term can activate quiescent lining cells to mature osteoblasts: unproven mechanism of the anabolic action of intermittent PTH. Proc 32nd Annual Meeting of the American Society for Bone and Mineral Research, Toronto, Ontario, Canada, 2010, p S46 (Abstract 1149)
241. Dobnig H, Turner RT 1995 Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136:3632-3638
242. Li X, Warmington K, Niu QT, Grisanti M, Tan H, Dwyer D, Stolina M, Simonet WS, Kostenuik PJ, Paszty C, KeHZ Increases in BMD observed with anti-sclerostin antibody treatment are reversible: a longitudinal OVX rat study. Proc 30th Annual Meeting of the American Society for Bone and Mineral Research, Honolulu, HI, 2008, p S60 (Abstract 1121)
243. Niu QT, Li X, Ke HZ Increased subchondral bone mass with no histological changes in articular cartilage in sclerostin knockout mice and rats treated with sclerostin monoclonal antibody. Transactions of the 58th Annual Orthopaedic Research Society Meeting, San Francisco, CA, 2012 Poster 0722244.
244. Li C, Ominsky MS, Tan HL, Barrero M, Niu QT, Asuncion FJ, Lee E, Liu M, Simonet WS, Paszty C, Ke HZ 2011 Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene. Bone 49: 1178-1185
245. McDonald MM, Morse A, Peacock L, Mikulec K, Kramer I, Kneissel M, Little D.G. Homozygous deletion of the SOST gene results in enhanced union and increased hard callus formation in healing fractures. Proc 32nd Annual Meeting of the American Society for Bone and Mineral Research, Toronto, Ontario, Canada, 2010, p S112 (Abstract FR0284)
246. Ke HZ, Xiang JJ, Li X, Simonet WS, Paszty C, Li G Inhibition of sclerostin by systemic treatment with a sclerostin monoclonal antibody enhances fracture healing in mice and rats. Transactions of the 55th Annual Orthopaedic Research Society Meeting, Las Vegas, NV, 2009: Paper 221
247. Li G, Song C, Li CY, Ke HZ Systemic treatment with sclerostin antibody significantly enhanced fracture healing in a mouse femoral osteotomy model: a time-course study. Transactions of the 56th Annual Orthopaedic Research Society Meeting, New Orleans, LA, 2010: Paper 483
248. HeYX, Liu Z, Tang T, Zheng LZ, ManCW, Li CY, Zhang G, Ke HZ, Qin L Inhibition of sclerostin by monoclonal antibody enhances bone healing in a rat osteotomy model. Proc 33rd Annual Meeting of the American Society for Bone and Mineral Research, San Diego, CA, 2011, p S374 (Abstract SU0464)
249. Li X, Grisanti M, Toupikov M, Davis S, Warmington KS, Lee TM, Niu QT, Lee E, Asuncion FJ Sclerostin inhibition by monoclonal antibody accelerates the bone healing process in an ovariectomized rat cortical defect model: an in vivo microCT study. Transactions of the 57th Annual Orthopaedic Research Society Meeting, Long Beach, CA, 2011: Paper 22
250. McDonald MM, Morse A, Mikulec K, Peacock L, Yu N, Baldock PA, Birke O, Liu M, Ke HZ, Little DG 27 March 2012 Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats. Journal of Orthopaedic Research, doi 10.1002/jor.22109.
251. Alaee F, Tang H, Ominsky MS, Ke HZ, Lieberman JR Sclerostin antibody enhances bone repair in a rat femoral defect model. Transactions of the 57th Annual Orthopaedic Research Society Meeting, Long Beach, CA, 2011: Poster 1474
252. Virk MS, Saquib SF, Alaee F, Lieberman JR Influence of sclerostin antibody on bone repair in a rat femoral defect model. Transactions of the 55th Annual Orthopaedic Research Society Meeting, Las Vegas, NV, 2009: Poster 607
253. Little DG, McDonald MM, Birke O, Morse A, Mikulec K, Peacock L, Liu M, Ke HZ Enhanced healing during distraction osteogenesis in rats with sclerostin antibody. Transactions of the 57th Annual Orthopaedic Research Society Meeting, Long Reach, CA, 2011: Poster 1475
254. Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P 2010 Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 25:2412-2418
255. Virdi A, Sena K, Maletich J, Liu M, Ke HZ, Sumner DR Bone implant fixation augmentation with anti-sclerostin antibody treatment in rats. Proc 31st Annual Meeting of the American Society for Bone and Mineral Research, Denvor, CO, 2009, p S375 (Abstract MO0018)
256. Virdi AS, Sena K, McNulty MA, Ke HZ, Liu M, Sumner DR Sclerostin antibody increases peri-implant bone formation in a rat ovariectomy model. Transactions of the 57th Annual Orthopaedic Research Society Meeting, Long Beach, CA, 2011: Paper 190
257. Shaffer AD, Shonuga OA, Hirsch BP, Cunningham M, Mait JE, Li C, Ke HZ, Lane JM Sclerostin antibody enhances spine fusion in a rat posterolateral transverse process fusion model: preliminary results. Proc 33rd Annual Meeting of the American Society for Bone and Mineral Research, San Diego, CA, 2011, p S517 (Abstract MO0461)
258. Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB 2007 Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 22:495-502
259. Li X, Grisanti M, Geng Z, Niu Q, Fan W, Daris M, Sheng J, Stolina M, Dwyer D, Simonet WS, Richards WG Dickkopf-1 delivery by adeno-associated virus caused bone loss in adult mice. Proc 28th Annual Meeting of the American Society for Bone and Mineral Research, Philadelphia, PA, 2006, p S8 (Abstract 1026)
260. GrisantiM, Niu QT, FanW, Asuncion F, Lee J, Steavenson S, Chen Q, Li J, Geng Z, Kostenuik P, Lacey DL, Simonet WS, Ominsky MS, Li X, Richards WG Dkk1 inhibition increases bone mineral density in rodents. Proc 28th Annual Meeting of the American Society for Bone and Mineral Research, Philadelphia, PA, 2006, p S25 (Abstract 1089)
261. Agholme F, Isaksson H, Kuhstoss S, Aspenberg P 2011 The effects of Dickkopf-1 antibody on metaphyseal bone and implant fixation under different loading conditions. Bone 48:988-996
262. Glantschnig H, Scott K, Hampton R, Wei N, McCracken P, Nantermet P, Zhao JZ, Vitelli S, Huang L, Haytko P, Lu P, Fisher JE, Sandhu P, Cook J, Williams D, Strohl W, Flores O, Kimmel D, Wang F, An Z 2011 A rate-limiting role for Dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody. J Pharmacol Exp Ther 338:568-578
263. Uderhardt S, Diarra D, Katzenbeisser J, David JP, Zwerina J, Richards W, Kronke G, Schett G. 2010 Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis 69:592-597
264. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, Mitsiades C, Prabhala R, Raje N, Anderson KC, Stover DR, Munshi NC 2009 Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114:371-379
265. Glantschnig H, Hampton RA, Lu P, Zhao JZ, Vitelli S, Huang L, Haytko P, Cusick T, Ireland C, Jarantow SW, Ernst R, Wei N, Nantermet P, Scott KR, Fisher JE, Talamo F, Orsatti L, Reszka AA, Sandhu P, Kimmel D, Flores O, Strohl W, An Z, Wang F 2010 Generation and selection ofnovel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem 285:40135-40147
266. Brommage R, Liu J, Bright DM, Smith DD, Jeter-Jone S, DaCosta M, Khounlo S, Shadon MK, Powell DR, Potter DG Elevated bone mass in mice treated with anti-dickkopf-1 neutralizing antibodies. Proc 32nd Annual Meeting of the American Society for Bone and Mineral Research, Toronto, Ontario, Canada, 2010, p S81 (Abstract 1263)
267. Richards WG, Grisanti M, Dwyer D, Niu QT, Asuncion FJ, Chen H, Jee WSS, Ke HZ, Stolina M, Ominsky MS, Li X Dkk1 inhibition promotes bone formation in growing, but not in aged osteopenic rats. Proc 33rd Annual Meeting of the American Society for Bone and Mineral Research, San Diego, CA, 2011, p S67 (Abstract 1206)
268. Wang FS, Ko JY, Yeh DW, Ke HC, Wu HL 2008 Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 149:1793-1801
269. Heiland GR, Zwerina K, Baum W, Kireva T, Distler JH, Grisanti M, Asuncion F, Li X, Ominsky M, Richards W, Schett G, Zwerina J 2010 Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis 69:2152-2159
270. Long L, Liu Y, Wang S, Zhao Y, Guo J, Yu P, Li Z 2010 Dickkopf-1 as potential biomarker to evaluate bone erosion in systemic lupus erythematosus. J Clin Immunol 30: 669-675
271. Dalbeth N, Pool B, Smith T, Callon KE, Lobo M, Taylor WJ, Jones PB, Cornish J, McQueen FM 2010 Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. Arthritis Res Ther 12:R164
272. Garnero P, Tabassi NC, Voorzanger-Rousselot N 2008 Circulating Dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept. J Rheum 35:2313-2315
273. Voorzanger-Rousselot N, Ben-Tabassi NC, Garnero P 2009 Opposite relationships between circulating Dkk-1 and cartilage breakdown in patients with rheumatoid arthritis and knee osteoarthritis. Ann Rheum Dis 68:1513-1514
274. Wang SY, Liu YY, Ye H, Guo JP, Li R, Liu X, Li ZG 2011 Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. J Rheum 38: 821-827
275. Yaccoby S, LingW, ZhanF, Walker R, Barlogie B, Shaughnessy Jr JD 2007 Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109:2106-2111
276. Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy Jr JD, Evans HR, Snowden JA, Stover DR, Vanderkerken K, Croucher PI 2009 Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 24:425-436
277. Edwards CM, Edwards JR, Lwin ST, Esparza J, Oyajobi BO, McCluskey B, Munoz S, Grubbs B, Mundy GR 2008 Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 111: 2833-2842
278. Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA 2006 A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 24:986-991
279. Padmanabhan S, Beck JT, Kelly KR, Munshi NC, Dzik-Jurasz A, Gangolli E, Ettenberg S, Miner K, Bilic S, Whyte W, Mehdi F, Chiang L-M, Rae PL, Spencer A, Shah J, Anderson KC, Giles FJ, Stewart AK A phase I/II study of BHQ880, a novel osteoblat activating, anti-DKK1 human monoclonal antibody, in relapsed and refractory multiple myeloma(MM)patients treated with zoledronic acid (Zol) and anti-myeloma therapy (MM Tx). Proc 51st Annual Meeting and Exposition of the American Society of Hematology, New Orleans, LA, 2009 (Abstract 750)